Cynvenio Biosystems, Inc.

Cynvenio Biosystems is dedicated to the development and commercialization of highly sensitive cell isolation technologies for blood-based cancer diagnostics, drug development and biomedical research.

Advances in genomic and proteomic science over the past decade have led to the development of targeted diagnostics and therapeutics that leverage the knowledge of an individual’s genetic makeup to create a more personalized approach to healthcare. Genomic testing enables the determination of an individual’s susceptibility to disease, predict how a patient will respond to a given drug, and match patients with the most effective therapeutics. This evolving science of individualized medicine has the potential to eliminate many unnecessary treatments, reduce the incidence of adverse reactions to drugs, increase the efficacy of treatments and ultimately, improve health outcomes.

Cynvenio’s rare cell detection and mutational profiling applications include newly-developed blood tests for the early detection of cancer and disease recurrence, and the selection of individual patient therapeutic solutions.